118 related articles for article (PubMed ID: 8991196)
1. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.
Lokiec F; Santoni J; Weill S; Tubiana-Hulin M
Anticancer Drugs; 1996 Nov; 7(8):893-6. PubMed ID: 8991196
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
Boddy AV; English M; Pearson AD; Idle JR; Skinner R
Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
Kerbusch T; Huitema AD; Ouwerkerk J; Keizer HJ; Mathôt RA; Schellens JH; Beijnen JH
Br J Clin Pharmacol; 2000 Jun; 49(6):555-61. PubMed ID: 10848719
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
Comandone A; Leone L; Oliva C; Frustaci S; Monteleone M; Colussi AM; Dal Canton O; Bergnolo P; Boglione A; Bumma C
J Chemother; 1998 Oct; 10(5):385-93. PubMed ID: 9822357
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2.
Passe P; Delepine N; Arnaud P; Urien S; Delepine G; Traoré F; Desbois JC; Brion F
Anticancer Res; 1999; 19(1B):837-42. PubMed ID: 10216502
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
[TBL] [Abstract][Full Text] [Related]
7. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
van Oosterom AT; Mouridsen HT; Nielsen OS; Dombernowsky P; Krzemieniecki K; Judson I; Svancarova L; Spooner D; Hermans C; Van Glabbeke M; Verweij J;
Eur J Cancer; 2002 Dec; 38(18):2397-406. PubMed ID: 12460784
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
Willits I; Price L; Parry A; Tilby MJ; Ford D; Cholerton S; Pearson AD; Boddy AV
Br J Cancer; 2005 May; 92(9):1626-35. PubMed ID: 15827549
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study.
Schrijvers D; Pronk L; Highley M; Bruno R; Locci-Tonelli D; De Bruijn E; Van Oosterom AT; Verweij J
Am J Clin Oncol; 2000 Aug; 23(4):358-63. PubMed ID: 10955864
[TBL] [Abstract][Full Text] [Related]
10. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
Baranzelli MC; Pichon F; Gourmel B; N'Guyen M; Deligny N; Demaille MC
Bull Cancer; 1997 Feb; 84(2):141-6. PubMed ID: 9180836
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
Kerbusch T; Mathĵt RA; Keizer HJ; Ouwerkerk J; Rodenhuis S; Schellens JH; Beijnen JH
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):467-77. PubMed ID: 11699611
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies.
Lopez AM; Ketchum M; Nichols H; Xu MJ; Peng YM; Dorr R; Alberts DS
Cancer Chemother Pharmacol; 2000; 46(5):411-5. PubMed ID: 11127946
[TBL] [Abstract][Full Text] [Related]
13. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
[TBL] [Abstract][Full Text] [Related]
14. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1996; 38(2):147-54. PubMed ID: 8616905
[TBL] [Abstract][Full Text] [Related]
15. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
16. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients.
Cerny T; Küpfer A; Zeugin T; Brunner KW
Ann Oncol; 1990 Sep; 1(5):365-8. PubMed ID: 2124500
[TBL] [Abstract][Full Text] [Related]
18. Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
Chugh R; Wagner T; Griffith KA; Taylor JM; Thomas DG; Worden FP; Leu KM; Zalupski MM; Baker LH
Cancer; 2007 Jun; 109(11):2315-22. PubMed ID: 17464949
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas.
Rassnick KM; Moore AS; Northrup NC; Kristal O; Beaulieu BB; Lewis LD; Page RL
Am J Vet Res; 2006 Mar; 67(3):510-6. PubMed ID: 16506919
[TBL] [Abstract][Full Text] [Related]
20. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
